GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Marketable Securities

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Marketable Securities : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Clinuvel Pharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2023 was $0.00 Mil.


Clinuvel Pharmaceuticals Marketable Securities Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Marketable Securities Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Clinuvel Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Clinuvel Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-29-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

3 High-Performing Stocks

By Alberto Abaterusso Alberto Abaterusso 07-12-2019

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

US FDA sets PDUFA date for SCENESSE®

By Marketwired Marketwired 01-10-2019

CLINUVEL delivers second positive financial result

By Marketwired Marketwired 08-29-2018

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022